Prevalence of 9p21 deletions in UK melanoma families

Genes Chromosomes and Cancer

Volumn 44, Issue 3, 2005, Pages 292-300

  Mistry, Sushila H ^a   Taylor, Claire ^a   Randerson Moor, Juliette A ^a   Harland, Mark ^a   Turner, Faye ^a   Barrett, Jennifer H ^a   Whitaker, Linda ^a   Jenkins, Robert B ^b   Knowles, Margaret A ^a   Bishop, Julia A Newton ^a   Bishop, D Timothy ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; CDKN2 GENE; CDKN2A GENE; CHROMOSOME 9P; CHROMOSOME DELETION; EXON; FAMILIAL CANCER; GENE AMPLIFICATION; GENE LOCUS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GERM LINE; HEMIZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MICROSATELLITE MARKER; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PEDIGREE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UNITED KINGDOM;

CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, NEOPLASM; FEMALE; GERM-LINE MUTATION; GREAT BRITAIN; HUMANS; MALE; MELANOMA; PEDIGREE; PREVALENCE; SKIN NEOPLASMS;

EID: 25844484591     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/gcc.20238     Document Type: Article

References (34)

1. Bahuau M, Vidaud D, Jenkins RB, Bleche I, Kimmel DW, Assouline B, Smith JS, Alderete B, Cayuela JM, Harpey JP, Caille B, Vidaud M. 1998. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 58:2298-2303.
2. Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, Peters G, Huot TJ, Bianchi-Scarra G, Lantieri F, Rodolfo M, Parmiani G, Pierotti MA. 2001. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer 85: 836-844.
3. Dracopoli NC, Fountain JW. 1996. CDKN2 mutations in melanoma. Cancer Surv 26:115-132.
4. FitzGerald MG, Harkin DP, Silva-Arrieta S, MacDonald DJ, Lucchina LC, Unsal H, O'Neill E, Koh J, Finkelstein DM, Isselbacher KJ, Sober AJ, Haber DA. 1996. Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci USA 93:8541-8545.
5. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AH, Palmer JM, Walters MK, Hayward NK, Fountain JW. 1997. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 15:2999-3005.
6. Gillanders E, Juo SH, Holland EA, Jones M, Nancarrow D, Freas-Lutz D, Sood R, Park N, Faruque M, Markey C, Kefford RF, Palmer J, Bergman W, Bishop DT, Tucker MA, Bressac-de Paillerets B, Hansson J, Stark M, Gruis N, Bishop JN, Goldstein AM, Bailey-Wilson JE, Mann GJ, Hayward N, Trent J. 2003. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73:301-313.
7. Gille JJ, Hogervorst FB, Pals G, Wijnen JT, van Schooten RJ, Dommering CJ, Meijer GA, Craanen ME, Nederlof PM, de Jong D, McElgunn CJ, Schouten JP, Menko FH. 2002. Genomic deletions of MSH2 and MLH1 in colorectal cancer families detected by a novel mutation detection approach. Br J Cancer 87:892-897.
8. Glendening JM, Flores JF, Walker GJ, Stone S, Albino AP, Fountain JW. 1995. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res 55:5531-5535.
9. Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, Kearns KS, Bale SJ, McBride OW, Clark WH, Jr., Tucker MA. 1993. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 52:537-550.
10. Goldstein AM, Goldin LR, Dracopoli NC, Clark WH, Jr., Tucker MA. 1996. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 58:1050-1056.
11. Goldstein AM, Chidambaram A, Halpern A, Holly EA, Guerry ID, Sagebiel R, Elder DE, Tucker MA. 2002. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res 12:51-55.
12. Harland M, Meloni R, Gruis N, Pinney E, Brookes S, Spurr NK, Frischauf AM, Bataille V, Peters G, Cuzick J, Selby P, Bishop DT, Bishop JN. 1997. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet 6:2061-2067.
13. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BA, Mann GJ, Bishop DT, Newton Bishop J. 2000. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 28: 45-57.
14. Harland M, Mistry S, Bishop DT, Bishop JA. 2001. A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees. Hum Mol Genet 10:2679-2686.
15. Harland M, Taylor CF, Bass S, Churchman M, Randerson-Moor J, Holland EA, Mann G, Bishop DT, Newton Bishop J. 2005. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees. Genes Chromosomes Cancer 43:128-136.
16. Hashemi J, Platz A, Ueno T, Stierner U, Ringborg U, Hansson J. 2000. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res 60:6864-6867.
17. Hashemi J, Lindstrom MS, Asker C, Platz A, Hansson J, Wiman KG. 2002. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF. Cancer Lett 180:211-221.
18. Hewitt C, Lee Wu C, Evans G, Howell A, Elles RG, Jordan R, Sloan P, Read AP, Thakker N. 2002. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11:1273-1279.
19. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C, Verhoef S, Schouten JP, van't Veer LJ, Pals G. 2003. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 63:1449-1453.
20. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH, Jr., Tucker MA, Dracopoli NC. 1994. Germline p16 mutations in familial melanoma. Nat Genet 8:15-21.
21. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. 1994. Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353-6358.
22. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McClure M, Aitken JF, Anderson DE, Bergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA. 1994. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8:23-26.
23. Kaufman DK, Kimmel DW, Parisi JE, Michels VV. 1993. A familial syndrome with cutaneous malignant melanoma and cerebral astrocytoma. Neurology 43:1728-1731.
24. Liu L, Goldstein AM, Tucker MA, Brill H, Gruis NA, Hogg D, Lassam NJ. 1997. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF. Genes Chromosomes Cancer 19:52-54.
25. Majore S, Catricala C, Binni F, De Simone P, Eibenschutz L, Grammatico P. 2004. CDKN2A: the IVS2-105A/G intronic mutation found in an Italian patient affected by eight primary melanomas. J Investig Dermatol 122:450-451.
26. Newton Bishop JA, Harland M, Benneu DC, Bataille V, Goldscein AM, Tucker MA, Ponder BA, Cuzick J, Selby P, Bishop DT. 1999. Mutation testing in melanoma families: INK4A, CDK4 and INK4D. Br J Cancer 80:295-300.
27. Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drusedan M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van't Veer LJ, Bakker E, van Ommen GJ, Devilee R 1997. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet 17:341-345.
28. Platz A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. 1997. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 89:697-702.
29. Randerson-Moor JA, Harland M, Williams S, Cuthbert-Heavens D, Sheridan E, Aveyard J, Sibley K, Whitaker L, Knowles M, Bishop JN, Bishop DT. 2001. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10:55-62.
30. Rizos H, Becker TM, Holland EA, Kefford RF, Mann GJ, 1997. Differential expression of p16INK4a and p16β transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 15:515-523.
31. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF. 2001. A melanoma-associated germline mutation in exon 1β inactivates p14ARF. Oncogene 20:5543-5547.
32. Scheuten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. 2002. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30:e57.
33. Sharpless E, Chin L. 2003. The INK4a/ARF locus and melanoma. Oncogene 22:3092-3098.
34. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. 1996. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12:97-99.